The European drugs regulator has found a “possible link” between the Johnson & Johnson vaccine and very rare blood clots detected in some recipients of the jab.
A warning over the clotting, which is combined with low blood platelet counts in the cases of concern, should be listed as a rare side effect for the vaccine, the safety committee for the European Medicines Agency said.
However, it insisted that the overall benefit of the jab in providing protection against Covid-19 far outweighs any associated risk.
The EMA found that all instances of clotting had occurred in adults under 60 years, mostly women, within three weeks of vaccination, adding that all available evidence, including eight reports of cases in the United States, were part of its assessment.
Based on the currently available evidence, specific factors that might heighten an individual’s chances of developing the blood clots have not been confirmed, the EMA said.
More to follow